The lawsuit alleges that the Defendants concealed their knowledge that Pradaxa can cause life threatening, irreversible bleeds from the Plaintiff, other consumers, the general public, and the medical community.
New York, New York (PRWEB) April 30, 2012
Parker Waichman LLP, a national law firm committed to protecting the legal rights of people injured by defective drugs, has filed a lawsuit on behalf of a Tennessee resident who suffered a cerebral hemorrhage, allegedly due to his use of the blood thinning drug, Pradaxa. The lawsuit, which was filed in U.S. District Court for the District of Connecticut on April 23, 2012, names Boehringer Ingelheim Pharmaceuticals, Inc. as a Defendant (Case No. 3:12-cv-00599-MRK).
According to the complaint, Pradaxa was approved by the U.S. Food and Drug Administration (FDA) in October of 2010 for prevention of stroke in patients with non-valvular atrial fibrillation. Pradaxa is the first new treatment alternative to warfarin (Coumadin) in nearly 60 years. The Defendants assert that Pradaxa has fewer drug interactions than warfarin, and the frequent laboratory tests needed to manage warfarin blood levels were not recommended for patients taking Pradaxa. Unlike warfarin, which is adjusted for individual patient blood levels on an ongoing basis, Pradaxa was approved in an allegedly easy “one size fits all” dose of 150 mg twice a day, according to the complaint.
The lawsuit states that in November 2011, Defendants confirmed at least 260 fatal bleeding events were reported in patients taking Pradaxa worldwide between March 2008 and October 2011. The complaint also points out that the FDA announced on December 7, 2011 that it had initiated an investigation into serious bleeding events associated with Pradaxa.
According to the lawsuit, the Plaintiff, a resident of Greenville County, Tennessee, was prescribed Pradaxa on or about February 22, 2011 and continued using the drug until approximately April 23, 2011. On or about April 23, 2011, he suffered a cerebral hemorrhage, as well as other severe personal injuries which are permanent and lasting in nature, physical pain and mental anguish, including diminished enjoyment of life, as well as the need for lifelong medical treatment, monitoring and/or medications, and fear of developing any of the above named health consequences all resulting from his ingestion of Pradaxa.
According to the complaint, Pradaxa levels in the blood are difficult or impossible to assess and bleeds cannot be stopped since there is no known reversal antidote for this dangerous drug. The lawsuit alleges that the Defendants concealed their knowledge that Pradaxa can cause life threatening, irreversible bleeds from the Plaintiff, other consumers, the general public, and the medical community. Among other things, Defendants did not warn of the irreversible nature of Pradaxa in the “Warnings and Precautions” section of the products initial warning label, according to the lawsuit.
The lawsuit charges the Defendants with, among other things Negligence; Strict Products Liability, including Failure to Warn, and Design, Marketing and Manufacturing Defects; Breach of Express and Implied Warranties; Fraudulent Misrepresentation; Negligent Misrepresentation; Deceptive Trade Practices; and Gross Negligence.
For more information about serious Pradaxa bleeding side effects, please view this video blog produced by Parker Waichman LLP.
Parker Waichman LLP is offering free lawsuit consultations to victims of Pradaxa bleeding side effects. If you or a loved one took Pradaxa and experienced a life-threatening bleeding event, please contact their office by visiting the firm's Pradaxa traumatic bleeding page at http://www.yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
For more information regarding Pradaxa bleeding lawsuits and Parker Waichman LLP, please visit: http://www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney